Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

MRI could serve as lumbar puncture proxy

Structural brain patterns on magnetic resonance imaging predict cerebrospinal fluid biomarker levels in patients with suspected Alzheimer’s disease or frontotemporal lobar degeneration, preliminary research suggests.

3 Jan 2013

Kareus announces start of KU-046 Phase I study in Alzheimer's

Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

3 Jan 2013

Molecular signals make some women prone to miscarriage

Scientists have identified molecular signals that control whether embryos are accepted by the womb, and that appear to function abnormally in women who have suffered repeated miscarriages.

3 Jan 2013

Prenatal brain development may be important influence on psychiatric risk later in life

Some brain changes that are found in adults with common gene variants linked to disorders such as Alzheimer's disease, schizophrenia, and autism can also be seen in the brain scans of newborns.

3 Jan 2013

UMDNJ-School of Osteopathic Medicine establishes Biomarker Discovery Center

Following recent discoveries by its researchers that could significantly change the diagnosis and treatment of a number of diseases, the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine has established the Biomarker Discovery Center on its Stratford campus.

3 Jan 2013

TFP5 molecule restores memory in mice with Alzheimer's

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restored-without obvious toxic side effects.

3 Jan 2013

News anchor shares experience about link between multiple sclerosis and dental mercury fillings

Nashville news anchor (Fox 17) Stacy Case will share her personal experience about the link between multiple sclerosis (MS) and dental mercury fillings on the January 3rd episode of CBS's The Doctors entitled "Dangerous Toxins."

2 Jan 2013

Nation-wide campaign to address myths and attitudes about dementia

Imagine a close friend tells you she has dementia. Would you avoid her for fear of being embarrassed by what she might say or do? According to a recent poll by Alzheimer's Disease International, 40 per cent of people with dementia reported they had been avoided or treated differently after diagnosis. It's no surprise, then, that one in four respondents cited stigma as a reason to conceal their diagnosis.

2 Jan 2013

Early problems in processing knowledge-based information linked to Alzheimer's disease

People who study or treat Alzheimer's disease and its earliest clinical stage, mild cognitive impairment (MCI), have focused attention on the obvious short-term memory problems. But a new study suggests that people on the road to Alzheimer's may actually have problems early on in processing semantic or knowledge-based information, which could have much broader implications for how patients function in their lives.

29 Dec 2012

Researchers develop unique approach to calpain inhibition

Calpain, a calcium-regulated enzyme, is essential to a host of cellular processes, but can cause severe problems in its overactivated state. It has been implicated as a factor in muscular dystrophy, AIDS, Alzheimer's disease, multiple sclerosis, and cancer. As such, finding and exploiting calpain inhibitors is an important area of research.

28 Dec 2012

New cost-effective, less invasive MRI method for diagnosis of dementia

A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Dec 2012

Alzheimer's disease or FTLD can be effectively tracked using MRI

When trying to determine the root cause of a person's dementia, using an MRI can effectively and non-invasively screen patients for Alzheimer's disease or Frontotemporal Lobar Degeneration (FTLD), according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

27 Dec 2012

Protein complex plays critical role in development of Alzheimer's disease

The Bonn site of the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn are leading contributors.

21 Dec 2012

UCLA study assesses prevalence of various types of study partners in Alzheimer's trials

For Alzheimer's disease researchers who conduct clinical trials, enrolling enough patients to make a trial meaningful is always a challenge. To enroll a single patient in a study requires not one but two participants - the patient and what's known as a study partner. Study partners provide the patient with support and update researchers about the patient's progress.

21 Dec 2012

Study identifies mechanisms responsible for regenerating blood vessels in the brain

New research from the University of Georgia identifies the mechanisms responsible for regenerating blood vessels in the brain.

20 Dec 2012

Study finds new signaling pathway involved in development of chronic inflammation of brain cells

The number of Alzheimer's patients will continue to dramatically increase in the next several decades. Various teams of researchers worldwide are feverishly investigating precisely how the illness develops. A

20 Dec 2012

FUS RNA binding ability essential for development of Amyotrophic Lateral Sclerosis

Research led by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, has found that the ability of a protein made by a gene called FUS to bind to RNA is essential to the development of Amyotrophic Lateral Sclerosis (ALS). This discovery identifies a possible therapeutic target for the fatal neurological disease.

20 Dec 2012

Scientists uncover TDP-43 protein as possible target for treatment of ALS, FTD

Neuroscientists at Georgetown University Medical Center say they have new evidence that challenges scientific dogma involving two fatal neurodegenerative diseases - amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) - and, in the process, have uncovered a possible therapeutic target as a novel strategy to treat both disorders.

20 Dec 2012

Positive top-line results from Idera’s IMO-3100 Phase 2a trial on plaque psoriasis

Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.

20 Dec 2012

Calif. advocates worry court-OK'd payment reductions will make it harder for poor to get care

Some worry that a Medicaid expansion in California could be hampered by reduced payments to Medi-Cal providers that a court approved last week, making it more difficult for the poor to find specialists.

18 Dec 2012

Alzheimer's Disease News and Research

Further Reading

MRI could serve as lumbar puncture proxy

Kareus announces start of KU-046 Phase I study in Alzheimer's

Molecular signals make some women prone to miscarriage

Prenatal brain development may be important influence on psychiatric risk later in life

UMDNJ-School of Osteopathic Medicine establishes Biomarker Discovery Center

TFP5 molecule restores memory in mice with Alzheimer's

News anchor shares experience about link between multiple sclerosis and dental mercury fillings

Nation-wide campaign to address myths and attitudes about dementia

Early problems in processing knowledge-based information linked to Alzheimer's disease

Researchers develop unique approach to calpain inhibition

New cost-effective, less invasive MRI method for diagnosis of dementia

Alzheimer's disease or FTLD can be effectively tracked using MRI

Protein complex plays critical role in development of Alzheimer's disease

UCLA study assesses prevalence of various types of study partners in Alzheimer's trials

Study identifies mechanisms responsible for regenerating blood vessels in the brain

Study finds new signaling pathway involved in development of chronic inflammation of brain cells

FUS RNA binding ability essential for development of Amyotrophic Lateral Sclerosis

Scientists uncover TDP-43 protein as possible target for treatment of ALS, FTD

Positive top-line results from Idera’s IMO-3100 Phase 2a trial on plaque psoriasis

Calif. advocates worry court-OK'd payment reductions will make it harder for poor to get care

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News